揭露默默的威胁:Cefepime诱导的血小板缺血症
Tutul Chowdhury1, Sailesh Karki1, Parvathy Anitha Rajeev1
1Internal Medicine, One Brooklyn Health-Interfaith Medical Center, Brooklyn, USA.
Cureus
|November 6, 2023
概括
塞费皮姆是第四代塞法洛斯波林,很少会导致血小板数的危险下降,即血小板数的危险下降. 这一案例凸显了在治疗时需要仔细监测血小板水平的必要性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
背景情况:
- 塞菲皮姆是一种广谱的第四代类抗生素抗生素.
- 对塞费皮姆的不良药物反应有记录,但血小板缺血是一种罕见的并发症.
研究的目的:
- 报告一名71岁男性患有塞费皮姆诱导的血小板缩病例.
- 讨论药物诱导的血小板缺血的机制.
- 为了强调在塞费皮姆治疗期间监测血小板数量的临床意义.
主要方法:
- 案例报告的呈现方式.
- 关于塞费皮姆诱导的血小板缺血机制的文献综述.
- 临床警和血小板计数监测.
主要成果:
- 一名71岁的男性患有血小板缺血症,这归因于塞费皮姆的使用.
- 塞费皮姆诱导的血小板缺血可能是骨髓抑制或免疫介导反应的结果.
- 早期发现和管理对于这种不良事件至关重要.
结论:
- 塞费皮姆可以诱导血小板缺血,这是一个罕见但严重的药物不良反应.
- 在塞菲皮姆治疗期间,监测血小板数量的提高警是必不可少的.
- 在临床实践中,识别和管理塞费皮姆诱导的血小板缺血症至关重要.
相关概念视频
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).